Digital Trials Digest, our quarterly newsletter
As decentralized trials scale, central rating workflows must keep pace. Here's a clear look at what central rating is, where it fits in trial operations, and why integrated platform delivery is changing the way sponsors manage independent endpoint review.
The conversation at SCOPE 2026 wasn't about what's possible in clinical trials — it was about why it's still so hard to execute. Here's what we heard on the ground.
Discover how simplifying vaccine logistics can make scientific breakthroughs truly global — and why digital innovation is the missing link in equitable access.
The FDA and OHRP have released new draft guidance providing recommendations for making the informed consent process as clear and comprehensive as possible for participants. Here's what you need to know.
Patient-reported outcomes are crucial components of every clinical trial—and they’re stronger and more accurate when captured electronically. Here’s what you need to know about PROs and ePROs.
In three short years, decentralized clinical trials (DCTs) have turned skeptics into believers. Trial sponsors who were once hesitant are now embracing the DCT model—and for good reason. Today’s DCTs are addressing longstanding industry challenges, expanding access to patients and clinicians, increasing diversity, accelerating cohort recruitment, and improving retention.
When it comes to decentralized clinical trials (DCTs), the pharmaceutical industry finds itself at a crossroads.
For patients with rare, incurable, or life-threatening diseases, clinical trials can offer new hope. Cancer patients, specifically, are often highly motivated to participate in research, particularly when they have an advanced or treatment-resistant form of cancer. Find out how decentralized clinical trials reach patients in the comfort of their homes.
While there's broad agreement on the gap between white and non-white participation in clinical trial enrollment, the number of non-white patients enrolled in clinical trials for general population studies is still quite low. But why?
Digital instruments such as sensors and wearables are transforming the industry’s definition of accuracy in three measures: volume, practicality, and precision.